CN106727926B

CN106727926B - Medicine for resisting hepatic fibrosis and treating liver cirrhosis and preparation method thereof

Info

Publication number: CN106727926B
Application number: CN201611136255.6A
Authority: CN
Inventors: 吕运一
Original assignee: Shenzhen Leafoo Biotechnology Co ltd
Current assignee: Shenzhen Leafoo Biotechnology Co ltd
Priority date: 2016-12-12
Filing date: 2016-12-12
Publication date: 2021-03-26
Anticipated expiration: 2036-12-12
Also published as: CN106727926A

Abstract

The invention relates to a medicine for resisting hepatic fibrosis and treating liver cirrhosis, which is prepared from 18-28 parts of tricholoma matsutake, 14-24 parts of duck meat, 7-17 parts of artemisia planisporus, 7-17 parts of ants, 3-8 parts of red ginseng and 2-7 parts of perilla oil by the steps of water extraction, stewing, drying and crushing. The pharmaceutical composition has no toxic or side effect, is easy to absorb, is suitable for resisting hepatic fibrosis and treating liver cirrhosis, and is also suitable for treating fatty liver, alcoholic liver and chemical liver injury. The invention also discloses a preparation method of the medicine for resisting hepatic fibrosis and treating liver cirrhosis.

Description

Medicine for resisting hepatic fibrosis and treating liver cirrhosis and preparation method thereof

Technical Field

The invention belongs to the field of national medicine preparations, and particularly relates to a medicine for resisting hepatic fibrosis and treating liver cirrhosis and a preparation method thereof.

Background

Liver diseases are frequently encountered diseases and common diseases in China. According to statistics, one hundred million and more than two thousand of hepatitis B virus carriers exist in China, and three thousand and more than ten thousand of liver disease patients needing to be treated exist. The number of patients who develop liver cirrhosis from related liver diseases is more than 30 million every year, the number of patients with liver cirrhosis in China is more than 200 million at present, about more than ten thousand people die of liver cirrhosis diseases every year in China, and the incidence rate and the death rate of liver cirrhosis are on the rising trend in recent years. Pathogenesis of fatty liver: the total liver fat of normal people accounts for about 5% of the liver weight, while the total liver fat of people with fatty liver can reach 40% -50%, mainly triglyceride and fatty acid. The pathogenesis of fatty liver is that the triglyceride is produced in a large amount or the very low density lipoprotein is in a small amount, so that the triglyceride is accumulated in the liver to form the fatty liver. The main causes of the diseases are the manifestations of metabolic disorders of the body in the liver, often caused by insulin resistance, glycolipid metabolic disorders, etc. About 20% of patients with fatty liver are steatohepatitis, 30-40% of patients with steatohepatitis can develop liver fibrosis, and 10-15% can develop liver cirrhosis. Pathogenesis of alcoholic liver disease: alcoholic liver is an inflammation of the liver caused by alcohol. Alcohol has toxicity to liver, more than 95% of alcohol taken into the body after drinking is catabolized in liver, the alcohol is oxidized into acetaldehyde under the action of alcohol dehydrogenase, the acetaldehyde is oxidized into acetic acid under the action of acetaldehyde dehydrogenase, the toxicity of acetaldehyde to liver cells is higher than that of alcohol, the acetaldehyde is a main factor causing chronic liver injury, can cause metabolic disorder of liver cells, can cause degeneration and necrosis of liver cells besides fatty liver, is complicated with inflammatory reaction, and can cause collagen fibers and nodule hyperplasia, liver failure, cholestasis, alcoholic hypoglycemia and other complications, and finally can cause liver cirrhosis. Drug induced liver injury: whether the drug enters the human body to cause liver injury or not depends mainly on the degree of damage of the drug to the liver and the response of the body to the drug. The damage of the medicine to the liver includes toxic liver damage and allergic liver damage. Toxic liver injury mainly causes hepatocyte necrosis, cholestasis and chronic drug poisoning; allergic liver injury causes mainly hepatocytes and immune pathological damage. Chemical liver injury: in daily life, chemical harmful substances, such as toxic substances, industrial three wastes (waste gas, waste water and waste residue) and pesticides are produced and used; vehicle exhaust gas, domestic soot and certain daily chemicals (such as alcohol) enter the liver through the gastrointestinal tract and blood circulation to be converted, so that the liver is easily damaged by the toxic substances, and chemical liver injury is caused. Pathogenesis of hepatic fibrosis: hepatic fibrosis is a pathological process of abnormal proliferation of fibrous connective tissue in the liver when hepatic cells are necrotic and inflamed, and is a repair reaction of an organism to liver parenchyma damage, and relative integrity of tissues and organs is maintained by filling and connecting fibers. Excessive fibrosis hardens the liver atrophy until cirrhosis decompensation or liver failure is caused. The vast majority of chronic liver diseases are liver fibrosis, of which about 25% to 40% eventually develop cirrhosis and even liver cancer. The main pathological changes of hepatitis are degeneration and necrosis of liver cells and proliferation of fibrous tissues. In severe acute hepatitis, hepatocytes are necrotic in large pieces in a short period of time, and the limiting plate stent collapses. After the recovery period, although the liver cells are actively regenerated, the new liver cells grow into an unordered cluster without being supported by the boundary plate, and the unordered liver cell cluster is a pseudo-lobule and has no physiological function. Overproduction and deposition of extracellular matrix is a central manifestation of liver fibrosis, with activated hepatic stellate cells being the major cellular source of extracellular matrix. Thus, hepatic stellate cell activation is a central link in the development of liver fibrosis. Therefore, cirrhosis is due to an imbalance in intrahepatic fibrogenesis and degradation, resulting in excessive deposition of extracellular matrix within the liver, which makes the liver atrophy and hard. The fibrous tissues in the liver grow fast, and the fibrous tissues can grow in rapidly while the fibrous tissues are necrotic and collapse in the boundary plates, so that the fibrous tissues are separated into strips and blocks. The liver necrosis was severe and the fibrous tissue was more hyperplastic. When fibrous tissues are not necrosed with the required nutrients to cause contraction, the liver becomes small and hard to develop into cirrhosis. Thus, liver fibrosis is a precursor lesion of liver cirrhosis, and liver cirrhosis is a result of further development of liver fibrosis, so that liver fibrosis and liver cirrhosis are a continuous development process. At present, the clinical aspects of resisting hepatic fibrosis and treating liver cirrhosis are not satisfactory, so that the difficulty in treating liver cirrhosis becomes a problem of general attention in the medical field.

Disclosure of Invention

The invention aims to overcome the defects of the prior art and provides a Chinese medicinal composition which has no toxic or side effect, is easy to absorb, is suitable for resisting hepatic fibrosis and treating liver cirrhosis, and is also suitable for treating fatty liver, alcoholic liver and chemical liver injury.

The invention also aims to provide a preparation method of the pharmaceutical composition.

The purpose of the invention is realized as follows:

a medicine for resisting hepatic fibrosis and treating liver cirrhosis is prepared by the following raw materials by weight through the steps of water extraction, cooking, drying and crushing:

18-28 parts of tricholoma matsutake, 14-24 parts of duck meat, 7-17 parts of artemisia annua

7-17 parts of ants, 3-8 parts of red ginseng and 2-7 parts of perilla oil.

Furthermore, the preferable mixture ratio of the raw materials of the medicine for resisting hepatic fibrosis and treating liver cirrhosis is as follows:

matsutake 18 parts duck meat 14 parts artemisia myristolochia 7 parts

7 parts of ants, 3 parts of red ginseng and 2 parts of perilla seed oil.

The preparation method of the medicine for resisting hepatic fibrosis and treating liver cirrhosis comprises the following steps:

crushing red ginseng, artemisia planisporum and tricholoma matsutake into 5mm coarse powder, mixing the coarse powder with ants, adding 14 times of water, decocting for two times, 1 hour each time, combining decoctions, concentrating the filtrate, and obtaining extract for later use;

providing perilla seed oil for later use;

③ mincing duck meat, mixing with perilla seed oil, adding water with the same amount, cooking for 1 hour by a pressure cooker, cooling, pulping, mixing the serous fluid with the extract, drying under reduced pressure, and pulverizing to obtain a fine powder preparation.

Further, the reduced pressure drying temperature is 55-65 ℃, the powder is crushed into fine powder, the fine powder is uniformly mixed with starch, 20% of starch slurry is used as an adhesive to prepare pills, and the pills are subpackaged into small bags after being dried.

The invention belongs to the field of Korean medicine preparations, and belongs to Korean medicine science. The Korean medicine and pharmacology is an important part of the traditional Chinese medicine and pharmacology, and the Chinese medicine and pharmacology gradually forms a traditional medicine and pharmacology system with unique theory and rich clinical experience by absorbing the theory of the traditional Chinese medicine and pharmacology and combining the practice of preventing and treating diseases by oneself on the basis of the Korean culture and the traditional medicine and pharmacology. The component analysis of the pharmaceutical composition of the invention: red ginseng: the records of the four elephants medical clinical guideline: invigorating primordial qi, quenching thirst, and promoting granulation; the record of "eastern medicine treasure-book" is: mild in nature, sweet in taste and non-toxic. Has effects in regulating qi deficiency of five viscera, calming mind, improving eyesight, promoting intelligence, treating asthenia, relieving cholera and vomiturition, treating consumptive lung disease and purulence, and eliminating phlegm; the record of "Buyi materia medica": sweet in taste, tonifying primordial qi, quenching thirst, promoting the production of body fluid, and regulating the health; record of the medical gate treasure inspection: sweet in taste, slightly warm, non-toxic and enters spleen and lung meridians. Invigorating qi, tranquilizing mind, eliminating pathogenic factors, improving intelligence, treating pain due to cold in heart and abdomen, relieving fullness in chest and hypochondrium, quenching thirst, resolving hard mass, strengthening qi, promoting digestion; the record of the east medical diagnosis and treatment dictionary is as follows: invigorating spleen and spleen; the "Korean Bing Yao Zhi" (records: invigorating spleen, invigorating primordial qi, quenching thirst, and promoting granulation. It can be used for treating yang exhaustion syndrome, asthenia, infantile yin toxin, and chronic infantile convulsion. Ants: has effects in nourishing yin, invigorating kidney, strengthening muscle and bone, resisting rheumatism, relieving inflammation and pain, protecting liver, reducing blood lipid, and enhancing immunity. Has two-way regulating effect on human body immunity, and has obvious inhibiting effect on fungi and staphylococcus aureus. The ant has obvious effects of strengthening body constitution and bone, strengthening vital qi to eliminate pathogenic factor, enhancing immunity and sexual function, building body, caring skin and resisting aging. In addition, it has good therapeutic effects on rheumatoid arthritis, rheumatism, sciatica, malignant tumor, chronic hepatitis, pulmonary tuberculosis, sexual impotence, premature ejaculation, spermatorrhea, poliosis, neurosis, and iron deficiency anemia. Artemisia annua: the "Korean Bing Yao Zhi" (records: artemisia iwayomogi is a medicine for people with shaoyin, and can promote diuresis and remove jaundice. Can be used for treating jaundice; the records of Yanbian medicinal plants: has antiinflammatory and diuretic effects, and can be used for treating jaundice and expelling intestinal parasites; the "court pharmacy" records: invigorating spleen, removing dampness and heat, and eliminating jaundice. It can be used for treating jaundice and female internal cold. The Korean nationality generally uses the product to prepare the ointment for treating the internal cold syndrome of women. Matsutake/mushroom: the mushroom has sweet and cool nature and flavor, enters intestines, stomach and lung channels, and has the effects of benefiting intestines and stomach, reducing phlegm, regulating qi and the like; record in the medical records, mushroom appetizes and stimulates the appetite; the mushroom is recorded in the raw materials record, and is beneficial to intestines and stomach, phlegm reducing and qi regulating; the Ming Dynasty Li Shizhen is called mushroom as mushroom in Ben Cao gang mu, the release name is meat mushroom, and the mushroom is sweet, cold and nontoxic, and can benefit intestines, stomach, resolve phlegm and regulate qi. Mushroom can regulate qi and resolve phlegm, and has good action on intestines and stomach. All herbs are damp and stagnated, and excessive eating is caused by internal qi obstruction, which causes many diseases, but not mushroom alone; the Wangshikang, a Qing Dynasty warm pathologist, is recorded in the 'Suanxiju diet book', mushrooms are sweet and cool, delicious in taste, suitable for both meat and vegetables, and excellent in appetite promotion, phlegm reduction, tenderness and no sand. The mushroom has effects of improving immunity, relieving pain, tranquilizing mind, relieving cough, eliminating phlegm, relaxing bowels, removing toxic substance, and resisting cancer. Perilla seed oil recorded in the book of Shayi materia medica: su you is sweet in flavor and cold in nature, can remove exogenous heat, and can moisten blood and treat deficiency cough and thirst. Has effects in protecting liver, resisting thrombi, reducing blood lipid, lowering blood pressure, protecting vision, improving intelligence, and inhibiting anaphylaxis and inflammation. Duck meat: the record of "eastern medicine treasure-book" is: cool in nature and non-toxic. Invigorating spleen and replenishing qi, regulating stomach qi, treating toxic heat wind, malignant sore and furuncle, and killing all parasites in abdominal organs; the record of "Buyi materia medica": the duck meat is sour and cold, and can be used for tonifying consumptive disease, edema, fright epilepsy and heat distension; record of the medical gate treasure inspection: sweet, salty, mild and nontoxic. Enter lung and kidney meridians. When it is used, it can nourish yin and remove dampness, make the lung to run the golden palace, and resolve deficiency-type phlegm to stop cough.

The medicine composition of the invention contains main medicines of ants for tonifying liver, nourishing yin and kidney, artemisia anomala for invigorating spleen, eliminating dampness and eliminating jaundice, and the main medicines are combined with each other for tonifying liver, tonifying kidney, invigorating spleen, eliminating dampness and eliminating jaundice. Ginseng radix Rubri can tonify primordial qi, treat deficiency, remove fullness in chest and hypochondrium, and break hard mass; the matsutake mushroom has the effects of regulating qi, eliminating phlegm, relaxing bowels, removing toxic substances, delaying aging, and resisting cancer; perilla seed oil has effects of protecting liver, tonifying deficiency, and moistening blood; the duck meat has the effects of invigorating spleen and replenishing qi, nourishing yin, eliminating phlegm, and killing all insects in abdominal organs. The traditional Chinese medicine composition combines the medicines to play the effects of tonifying middle-jiao and Qi, tonifying liver and kidney, invigorating spleen and eliminating dampness, regulating vital energy and reducing phlegm, removing blood stasis and resolving hard mass, and promoting blood circulation and removing toxin.

The pharmaceutical composition disclosed by the invention is a mechanism which plays a role in protecting liver cells by protecting cell membranes, removing oxygen radicals and inhibiting lipid peroxidation through researching a protection action mechanism of tetrachloro mouse acute liver injury, and provides a reference basis for clinical hepatic fibrosis resistance and liver cirrhosis treatment.

The dosage form of the pharmaceutical composition is pills, about 10 pills are contained in 1 gram of the pharmaceutical composition, and 9 grams of pills are filled in each small bag.

The taking method of the finished product of the pharmaceutical composition comprises the following steps: the preparation is taken with warm boiled water 30 min before meal for 3 times a day, 1 bag (9 g/bag) each time. Three months is taken as a treatment course.

Clinical trials of the pharmaceutical compositions of the present invention were analyzed using example 5 as a standard.

The finished product of the pharmaceutical composition is also called 'artemisia praeparata liver-recovering pill/SHGKW'. Clinical cases are provided by the hospital in the frontier.

Case 1: Huang-Shi, male, 38 years old. After long-term drinking, the patient has complaints of weakness, fatigue, abdominal distension and pain in the liver area, and the patient stays in the hospital for many times, the ultrasonic display of the hospital shows that the liver cirrhosis and the ascites have obvious abnormal detection indexes of various serums, and the diagnosis result is as follows: alcoholic cirrhosis, ascites.

Serological test index before and after treatment of patients

The patient takes the pharmaceutical composition of the invention for 10 months, takes the diuretic with small dosage in the previous month, gradually gets better after the discomfort symptom is 1 month, does not take other medicines, does not lose albumin all the time, the state of illness is stable, and the change of the liver shape and serological indexes is as the table above.

Case 2: wu Chi, female, 38 years old. The diagnosis result is that the patient is in line with the morphological change of liver cirrhosis, the serological detection has obvious abnormal indexes, and the diagnosis result is that: chronic hepatitis c, liver cirrhosis.

Serological test index before and after treatment of patients

After the patient takes the pharmaceutical composition for treatment for 7 months, the discomfort symptoms are gradually improved after two months, the patient takes 'Anli' nutritional protein and vitamins by himself during the treatment process, other medicines are not used, the state of the disease is stable, the patient lives normally, and the liver morphology and the serological index change as shown in the table.

Case 3: plum, male, 51 years old, has definite hepatitis B history for more than 20 years, often general debilitation, abdominal distension, liver pain, severe dyspepsia, multiple hospitalizations, hospital ultrasonic display, early cirrhosis change, serological detection part abnormality, and diagnosis results: hepatitis B, early stage cirrhosis.

Serological test index before and after treatment of patients

The patient takes the pharmaceutical composition of the invention for 7 months, the maladaptive symptoms are gradually improved, other medicines are not used in the treatment process, the state of illness is stable, the patient lives normally, and the liver morphology and the serum indexes are shown in the table.

Case 4: pu Shi, male, 42 years old. The clinical history of hepatitis B is clear for 12 years, the patients often have hypodynamia, inappetence and liver pain, the liver is obviously reduced by ultrasonic display in hospitals, multiple detection indexes in serology are obviously abnormal, and the diagnosis results in hospitals are as follows: chronic hepatitis B, liver cirrhosis.

Serological test index before and after treatment of patients

After the patient is treated by taking the pharmaceutical composition for 12 months, the maladaptive symptoms are gradually improved, other medicines are not used in the treatment process, the condition is stable, the digestion is good, the patient is energetic, and the liver morphology and serology indexes are shown in the table.

Case 5: zhangqi, male, age 59. The long-term large-scale drinking, the self-complaint is acratia, dyspepsia, abdominal distension, liver area pain, the ultrasonic display of hepatic fibrosis in hospitals, liver elasticity value: stiffness17.6, diagnosis: the method conforms to the morphological change of the liver cirrhosis, and multiple detection indexes of serology are obviously abnormal.

Serological test index before and after treatment of patients

After the patient takes the pharmaceutical composition of the invention for 6 months, the ultrasonic display of the hepatic fibrosis in the hospital and the elasticity value of the liver are as follows: stiffness7.9, the symptoms of maladaptation gradually improved, no other drugs were used during the treatment, and the liver morphology and serology indexes are shown in the table above.

Case 6: sunzhi, female, 50 years old. The patient self-complains of tiredness and weakness, sometimes feels discomfort in the right upper abdomen, the hepatic fibrosis ultrasonic display in the hospital, and the liver elasticity value: stiffness16.6, severe hepatic fibrosis is diagnosed, multiple detection indexes of serology are obviously abnormal, and the diagnosis result is as follows: severe liver fibrosis. .

Serological test index before and after treatment of patients

The patient is treated for 4 months by taking the pharmaceutical composition of the invention, the ultrasonic display of the hepatic fibrosis in the hospital, the liver elasticity value: stiffness8.6, the symptoms gradually improved, no other drugs were used during the treatment, and the liver morphology and serology indices are shown in the table above.

Animal experiments

The medical college of Yanbian university completes the protection effect of the pharmaceutical composition on the tetrachloro mice acute liver injury.

As a result: the influence of the pharmaceutical composition on the serum ALT activity of mice with acute liver injury caused by carbon tetrachloride

As seen from Table 1, ALT activity of the model control group was significantly increased as compared with that of the normal control group. The difference has statistical significance (P is less than 0.01), which indicates that the establishment of the mouse acute liver injury model caused by carbon tetrachloride is successful; compared with a model control group, the serum ALT activity of the large, medium and small dose groups of the pharmaceutical composition is obviously reduced, and the comparison difference has statistical significance (P is less than 0.01), which prompts that the pharmaceutical composition can obviously inhibit the increase of the serum ALT activity of mice with acute liver injury caused by carbon tetrachloride.

The composition of the invention has the effects on the SOD, GSH-Px activity and MDA content of liver tissues of mice with acute liver injury caused by carbon tetrachloride

As can be seen from Table 1, compared with the model control group, the liver tissue SOD and GSH-Px activity of the mice with large, medium and small dose of the pharmaceutical composition are obviously improved, the MDA content is obviously reduced, and the comparison difference has statistical significance (P is less than 0.01 and P is less than 0.05), which indicates that the pharmaceutical composition can improve the activity reduction of liver tissue SOD and GSH-Px of mice with acute liver injury caused by carbon tetrachloride and simultaneously reduce the MDA content.

TABLE 1 Effect of the pharmaceutical composition of the present invention on serum ALT activity, liver tissue SOD, GSH-Px activity and MDA content (x + -SD, n = 10) of mice with acute liver injury caused by carbon tetrachloride

The experimental result shows that the administration of the pharmaceutical composition of the invention has obvious inhibition effect on the elevation of the serum ALT activity of mice caused by carbon tetrachloride. The ability of the liver cirrhosis patients to scavenge free radicals is significantly reduced due to the low liver function. A large number of research results at home and abroad show that the occurrence and development of liver diseases such as hepatitis, liver cirrhosis, fatty liver, liver cancer, alcoholic liver and the like are closely related to free radical damage, and the clinical application of the free radical scavenger has good effect on treatment. Free radicals are intermediate products in the normal biochemical process of a human body, exist in the normal and pathological processes of the human body, and simultaneously, the human body obtains some enzymes for inactivating oxygen free radicals, such as SOD, GSH-Px and the like, in the evolution process, and the free radicals are important antioxidant enzymes in the human body and play roles in protecting the structural and functional integrity of cell membranes. MDA is the final product of lipid peroxidation, which can seriously damage the structure of cell membrane, causing cell swelling and necrosis, and its content can reflect the damage degree of tissue peroxidation. The experimental result shows that the activity of SOD and GSH-Px in liver tissues of mice in large, medium and small dose groups of the pharmaceutical composition is obviously improved compared with that of a model control group, and the content of MDA is obviously reduced, which indicates that the pharmaceutical composition can protect liver cells by protecting cell membranes, removing oxygen free radicals and inhibiting lipid peroxidation.

Detailed Description

Example 1

A pharmaceutical composition for resisting hepatic fibrosis and treating liver cirrhosis is prepared from the following raw materials by weight through the steps of water extraction, cooking, drying and crushing: 18-28 parts of tricholoma matsutake, 14-24 parts of duck meat, 7-17 parts of artemisia japonica, 7-17 parts of ants, 3-8 parts of red ginseng and 2-7 parts of perilla oil.

The preparation method comprises the following steps:

② perilla seed oil is prepared by squeezing perilla seed for standby;

thirdly, mincing duck meat, mixing with perilla oil, adding water with the same amount, cooking for 1 hour by using a pressure cooker, cooling, pulping, mixing the pulp with the extract, drying under reduced pressure at 55-65 ℃, crushing into fine powder, adding a proper amount of starch (or starch with the same amount), uniformly mixing, preparing pills by using 20% of starch slurry as an adhesive, drying, and subpackaging into small bags to obtain the finished product of the pharmaceutical composition.

Example 2

A medicine for resisting hepatic fibrosis and treating liver cirrhosis is prepared by the following raw materials by weight through the steps of water extraction, cooking, drying and crushing: 18-26 parts of tricholoma matsutake, 14-22 parts of duck meat, 7-15 parts of artemisia japonica, 7-15 parts of ants, 3-6 parts of red ginseng and 2-5 parts of perilla oil.

Example 2 the preparation of the drug was the same as in example 1.

Example 3

A medicine for resisting hepatic fibrosis and treating liver cirrhosis is prepared by the following raw materials by weight through the steps of water extraction, cooking, drying and crushing: 20-25 parts of tricholoma matsutake, 16-20 parts of duck meat, 9-13 parts of artemisia japonica, 9-13 parts of ants, 5-6 parts of red ginseng and 4-5 parts of perilla oil.

Example 3 the preparation of the drug is the same as in example 1.

Example 4

A pharmaceutical composition for resisting hepatic fibrosis and treating liver cirrhosis is prepared from the following raw materials by weight through the steps of water extraction, cooking, drying and crushing: 18-24 parts of tricholoma matsutake, 14-19 parts of duck meat, 7-13 parts of artemisia japonica, 7-13 parts of ants, 3-6 parts of red ginseng and 2-5 parts of perilla oil.

Example 4 the pharmaceutical composition was prepared according to the same method as in example 1.

Example 5

A pharmaceutical composition for resisting hepatic fibrosis and treating liver cirrhosis is prepared from the following raw materials by weight through the steps of water extraction, cooking, drying and crushing: 18 parts of tricholoma matsutake, 14 parts of duck meat, 7 parts of artemisia montana, 7 parts of ants, 3 parts of red ginseng and 2 parts of perilla oil.

Example 5 the preparation of the pharmaceutical composition is the same as in example 1.

The use of the examples of the invention is merely to illustrate the invention and is not intended to limit the scope of the invention. Further, various changes, modifications and variations may be suggested to one skilled in the art after reading the present specification, and all such equivalents are intended to be included within the scope of the present invention as defined in the following claims.

Claims

1. A medicine for resisting hepatic fibrosis and treating liver cirrhosis is prepared by the following raw materials by weight through the steps of water extraction, cooking, drying and crushing: 18 parts of tricholoma matsutake, 14 parts of duck meat, 7 parts of artemisia montana, 7 parts of ants, 3 parts of red ginseng and 2 parts of perilla oil;

the preparation method of the medicine comprises the following steps:

providing perilla seed oil for later use;

thirdly, grinding duck meat, mixing with perilla oil, adding water with the same amount, cooking for 1 hour by using a pressure cooker, cooling, pulping, mixing the serous fluid with the extract, drying under reduced pressure, and crushing into a fine powder preparation;

the reduced pressure drying temperature is between 55 ℃ and 65 ℃, the powder is crushed into fine powder, the fine powder is uniformly mixed with starch, 20 percent starch slurry is used as a bonding agent to prepare pills, and the pills are subpackaged into small bags after being dried.

2. A method for preparing the anti-hepatic fibrosis and liver cirrhosis medicament of claim 1, comprising the steps of:

providing perilla seed oil for later use;

thirdly, mincing duck meat, mixing with perilla oil, adding water with the same amount, cooking for 1 hour by using a pressure cooker, cooling, pulping, mixing the pulp with the extract, drying under reduced pressure at the temperature of 55-65 ℃, crushing into fine powder, uniformly mixing with starch, preparing pills by using 20% of starch slurry as an adhesive, drying, and subpackaging into small bags.